secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0001104659-24-114097
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Pharma Q3 2024 net loss $4.2M; NXP800 data update expected November
----------------------------------------------------------------------------

- Net loss $4.2M in Q3 2024 vs $5.9M Q3 2023; R&D expenses $2.8M vs $4.5M.
- Cash, cash equivalents and short-term investments $17.2M as of Sep 30, 2024 (vs $19.1M Dec 31, 2023); runway into 2026.
- NXP800 Phase 1b clinical data update expected November 2024; received FDA Orphan Drug Designation for ARID1a-deficient ovarian cancers.
- NXP900 Phase 1a dose escalation: 4 cohorts completed with no DLTs; dose continuing; combo plans in NSCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465924114097/0001104659-24-114097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465924114097/tm2427419d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-114097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer